~~13. An anti-FcRn antibody or binding fragment thereof which binds to the same epitope of human FcRn as the antibody of claim 3.~~

~~14. An anti-FcRn antibody or binding fragment thereof which binds an epitope of human FcRn which comprises at least one amino acid selected from the group consisting of residues V105, P106, T107, A108 and K109 of SEQ ID NO:94 and at least one residue selected from the group consisting of P100, E115, E116, F117, M118, N119, F120, D121, L122, K123, Q124, G128, G129, D130, W131, P132 and E133 of SEQ ID NO:94.~~

~~15. An anti-FcRn antibody or binding fragment thereof according to claim 13 or claim 14 which is humanized or fully human.~~

~~16. An anti-FcRn antibody or binding fragment thereof according to any one of claims 13 to 15 which has a binding affinity for human FcRn of 100pM or less.~~

~~17.~~13. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to ~~16~~12 which blocks binding of human IgG to human FcRn.

~~18.~~14. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to ~~17~~13 which does not bind β2 microglobulin.

~~19.~~15. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to ~~18~~14.

~~20.~~16. A cloning or expression vector comprising one or more DNA sequences according to claim ~~19~~15.

~~21.~~17. A vector according to claim ~~20~~16, wherein the vector comprises (i) the sequence given in SEQ ID NO:37 and the sequence given in SEQ ID NO:23 or (ii) the sequence given in SEQ ID NO:80 and the sequence given in SEQ ID NO:79 or (iii) the sequence given in SEQ ID NO:93 and the sequence given in SEQ ID NO:91.

~~22.~~18. A host cell comprising one or more cloning or expression vectors according to claim ~~20~~16 or claim ~~21~~17.

~~23.~~19. A process for the production of an antibody having binding specificity for human FcRn, comprising culturing the host cell of claim ~~22~~18 and isolating the antibody.

~~24.~~20. A pharmaceutical composition comprising an anti-FcRn antibody or binding fragment thereof as defined in any one of claims 1 to ~~18~~14 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

~~25.~~21. A pharmaceutical composition according to claim ~~24~~20, additionally comprising other active ingredients.

~~26.~~22. An antibody or binding fragment thereof as defined in any one of claims 1 to ~~18~~14 or a composition as defined in claim ~~24~~20 or ~~25~~21 for use in therapy.

~~27.~~23. An antibody or binding fragment thereof as defined in any one of claims 1 to ~~18~~14 or a composition as defined in claim ~~24~~20 or ~~25~~21, for use in the treatment of an autoimmune disease, such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, Idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.